Last updated: February 27, 2026
What Is the Therapeutic Classification and Market Position?
NDC 57664-0649 is marketed as Ryasphere (Crisaborole 2%) ointment, a topical phosphodiesterase-4 (PDE4) inhibitor indicated for the treatment of atopic dermatitis, primarily in pediatric and adult patients. Approved by the FDA in December 2016, Ryasphere has positioned itself within the dermatology market targeting moderate to severe atopic dermatitis.
Current Market Landscape
Competition and Market Share
Ryasphere competes primarily with topical corticosteroids, calcineurin inhibitors, and other PDE4 inhibitors approved for dermatitis (e.g., Eucrisa). The key competitors include:
| Product Name |
Active Ingredient |
Market Launch Year |
Estimated 2022 US Prescriptions |
Share in Atopic Dermatitis Treatment (%) |
| Eucrisa (crisaborole) |
Crisaborole (topical PDE4 inhibitor) |
2016 |
1.2 million |
25 |
| Topical corticosteroids |
Various (hydrocortisone, clobetasol) |
1950s–2000s |
4.8 million |
60 |
| Calcineurin inhibitors |
Tacrolimus, pimecrolimus |
2000s |
1.5 million |
15 |
Market Trends
The atopic dermatitis market in the US reached approximately $1.9 billion in 2022, growing at a compound annual growth rate (CAGR) of 7%. Demand driven by increasing prevalence, especially in pediatric populations, and a shift toward steroid-sparing therapies favoring PDE4 inhibitors.
Prescriptions and Utilization
Prescriptions for crisaborole increased 10-12% annually, with a recent plateau correlating to the availability of more effective therapies like biologics (dupilumab).
Pricing Environment
Ryasphere's average wholesale price (AWP) in 2022 was approximately $650 per 60g tube, translating into a per-treatment course cost of ~$520. Contract discounts and insurance coverage significantly impact net pricing.
Price Projections and Future Outlook
Short-term Price Trends (Next 1-2 years)
- Prices are expected to stabilize in the range of $600-$650 per tube.
- Insurance negotiations and formulary placements influence access and reimbursement.
- Market share is expected to remain steady at approximately 25%, constrained by competition from corticosteroids and emerging drugs.
Long-term Price Trends (Next 3-5 years)
- Patent exclusivity is set to expire in 2025, allowing generics to enter the market.
- Generic crisaborole likely to price 30-50% below branded, reducing revenue substantially.
- Market share of branded Ryasphere anticipated to decline to below 10% within three years post-generic entry.
- Price erosion expected to amplify as generics gain approval and market penetration.
Impact of Biosimilars and Emerging Therapies
- The rise of systemic biologics (dupilumab, adagrasib) for severe dermatitis could further restrict the pediatric and mild-moderate market share.
- New topical agents with improved efficacy and safety profiles are under development, potentially impacting demand and pricing of existing drugs like Ryasphere.
Regulatory and Policy Considerations
- The FDA's push for value-based pricing and increased biosimilar competition could pressure prices.
- Medicare, Medicaid, and private plans may implement stricter step therapy, affecting net revenue.
Summary Table: Price and Revenue Projections
| Year |
Brand Price per Tube |
Estimated Market Share |
Predicted Revenue |
Comments |
| 2023 |
$640 |
25% |
$250 million |
Stable pricing, competition limits growth |
| 2024 |
$620 |
20% |
$200 million |
Slight decline as prescriber preference shifts |
| 2025 |
$560 |
10% |
$100 million |
Generic entry expected, steep revenue decline |
| 2026+ |
$300 - $400 (generic) |
0-10% (branded) |
$0-50 million |
Branded market diminishes; generics dominate |
Key Takeaways
- Ryasphere remains a valuable dermatology asset through 2024, with stable pricing and moderate market share.
- Patent expiration in 2025 will cause significant price erosion and revenue decline.
- Competitive pressures from generics, biologics, and emerging therapies will reshape the market, necessitating strategic R&D investments or licensing deals.
- Insurance and health policy trends will influence product uptake and net revenue.
FAQs
1. What factors influence Ryasphere’s pricing stability?
Pricing stability depends on formulary positioning, insurance reimbursement, and the absence of generic competition until patent expiry.
2. How soon will generics impact revenue?
Generics are expected to enter the market post-2025, likely causing a 30-50% price drop and reduced branded market share.
3. Can biosimilars affect the topical dermatitis market?
Biosimilars are generally applicable to biologics; topical PDE4 inhibitors like crisaborole are less impacted due to different formulations, but new topical agents may challenge Ryasphere’s market position.
4. How does the market for atopic dermatitis develop?
Prevalence continues to rise, especially among children, driving increased demand for both topical and systemic therapies.
5. What are alternative treatments likely to impact Ryasphere in the next five years?
Biologics like dupilumab and emerging topical agents with improved safety profiles could further limit Ryasphere’s growth prospects.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2016). FDA approves Crisaborole ointment for atopic dermatitis.
[3] EvaluatePharma. (2023). Topical dermatological drugs market report.
[4] Centers for Disease Control and Prevention. (2022). Prevalence of atopic dermatitis.
[5] Drug Channels Institute. (2023). Drug pricing and reimbursement trends.
Note: The projections are based on current market data and trends. Actual outcomes may vary with regulatory, competitive, and policy changes.
